Technical Analysis for RAIN - Rain Therapeutics Inc.

Grade Last Price % Change Price Change
D 15.33 1.66% 0.25
RAIN closed up 1.66 percent on Friday, May 14, 2021, on 89 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical RAIN trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
New 52 Week Closing Low Bearish 1.66%
Hot IPO Pullback Bullish Swing Setup 1.66%
New 52 Week Low Weakness 1.66%
Outside Day Range Expansion 1.66%
Down 3 Days in a Row Weakness 1.66%
Down 4 Days in a Row Weakness 1.66%
Hot IPO Pullback Bullish Swing Setup -3.65%
Down 3 Days in a Row Weakness -3.65%
Older End-of-Day Signals for RAIN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 10 hours ago
Possible Inside Day about 11 hours ago
Down 2 % about 14 hours ago
Down 1% about 14 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Classification

Sector: Other
Industry: Other
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancers Prostate Cancer Antineoplastic Drugs Tumors Targeted Therapy Tyrosine Kinase Receptors Bemcentinib

Is RAIN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.9
52 Week Low 14.08
Average Volume 208,599
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 16.68
Average True Range 1.78
ADX 0.0
+DI 11.65
-DI 19.73
Chandelier Exit (Long, 3 ATRs ) 18.55
Chandelier Exit (Short, 3 ATRs ) 19.43
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.21
MACD Signal Line -0.05
MACD Histogram -0.1611
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.22
Resistance 3 (R3) 17.19 16.54 16.91
Resistance 2 (R2) 16.54 16.06 16.55 16.80
Resistance 1 (R1) 15.93 15.76 16.24 15.96 16.69
Pivot Point 15.28 15.28 15.43 15.29 15.28
Support 1 (S1) 14.67 14.80 14.98 14.70 13.97
Support 2 (S2) 14.02 14.50 14.03 13.86
Support 3 (S3) 13.41 14.02 13.76
Support 4 (S4) 13.44